You are here

FDA Rejects Cancer Drug, Melblez (Melphalan)

Drug treats rare eye cancer that spreads to the liver (September 13)

The FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for the Melblez Kit (Melblez [melphalan] for Injection for use with the Delcath Hepatic Delivery System) for the treatment of patients with unresectable ocular melanoma metastatic to the liver.

A CRL is issued by the FDA when the review of a file is completed and questions remain that preclude approval of the NDA in its current form.

The FDA comments included a statement that the drug’s developer (Delcath Systems, Inc.) must perform another “well-controlled randomized trial to establish the safety and efficacy of [the] Melblez Kit using overall survival as the primary efficacy outcome measure,” and which “demonstrates that the clinical benefits of [the] Melblez Kit outweigh its risks.”

In a clinical trial, 7% of 122 patients died due to side effects related to treatment with the kit.

About 4 months ago, an independent panel of FDA advisors unanimously recommended against approving the therapy.

Sources: Delcath Systems, Inc.; September 13, 2013; and Reuters; September 13, 2013.

Recent Headlines

Superior to Quinine in Reducing Mortality in Two Clinical Trials
Minimally Invasive Method Reduces Regurgitation and Leaking
Neurofilament Light Protein Correlated With Accumulated Brain Damage
Technology Designed to Improve Patient Care, Limit Infections
Medical Device Enables Nerve Stimulation During Sleep
May Offer Improved Safety Profile for Pediatric Patients
Hope for Sufferers With Post-Treatment Lyme Disease Syndrome
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
Possible First Treatment Option for Rare Autoimmune Disease of the CNS